课题基金 / 基金详情

Isozyme specific effects of PKCs in thyroid cells

Isozyme specific effects of PKCs in thyroid cells
甲状腺细胞中 PKC 的同工酶特异性作用
批准号:
6918452
负责人:
JUDY L MEINKOTH
金额:
$26.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-04-01 至 2010-03-31

项目摘要

项目成果

JUDY L MEINKOTH的其他基金

相似基金

相关文献

中文摘要
翻译
简介(申请人提供):甲状腺肿瘤是最常见的内分泌恶性肿瘤。据估计,在这个国家进行的尸检中,高达90%的人发现了生长缓慢的甲状腺肿瘤。虽然分化良好的滤泡和乳头状甲状腺肿瘤预后良好,但间变性甲状腺肿瘤可迅速致命。激活Ras突变在人类甲状腺肿瘤中尤为普遍。Ras突变见于良性腺瘤,在滤泡癌和间变性癌中频率更高。B-Raf (Ras的下游效应因子)的突变是甲状腺乳头状瘤中最常见的突变事件。这些观察结果支持Ras在甲状腺肿瘤的发生和发展中的作用。很大比例的甲状腺乳头状肿瘤表现出PKCepsilon基因的扩增和重排,导致PKCepsilon的n端片段的表达,其结构类似于V1结构域,这是一种选择性抑制PKCepsilon易位的肽。有趣的是,大多数乳头状甲状腺肿瘤表现出PKCepsilon的表达降低。此外,RET/PTC癌基因的表达诱导选择性易位,随后PKCepsilon下调。PKCalpha表达在滤泡性甲状腺肿瘤中增加,这些肿瘤也含有Ras突变。我们的假设是,PKC同工酶在Ras介导的甲状腺细胞转化的启动和维持中发挥了重要作用。我们的初步数据表明,PKCdelta选择性地再现了致癌Ras对异常细胞周期进程和凋亡的急性影响;ras诱导的形态学改变需要PKCepsilon;PKCs模拟Ras对甲状腺分化的抑制作用;ras转化的甲状腺细胞表现出PKC表达和活性的改变。本研究旨在探讨PKC同工酶在大鼠甲状腺细胞Ras转化的启动和维持中的作用。这将使用高度特异性的分子试剂来完成,包括PKC同工酶的腺病毒,选择性PKC肽激活剂和抑制剂以及RNA干扰。这一分析将为Ras失调甲状腺细胞增殖、分化和存活的分子机制提供新的见解,并可能导致新策略的发展,以选择性地损害肿瘤细胞增殖和/或重新激活分化基因表达。
英文摘要
DESCRIPTION (provided by applicant): Thyroid tumors are the most common endocrine malignancy. It has been estimated that up to 90% of the autopsies performed in this country reveal the presence of slow-growing thyroid tumors. While the prognosis for patients with well-differentiated follicular and papillary thyroid tumors is good, anaplastic thyroid tumors are rapidly fatal. Activating Ras mutations are particularly prevalent in human thyroid tumors. Ras mutations are found in benign adenomas and at a higher frequency in follicular and anaplastic carcinomas. Mutations in B-Raf, a downstream Ras effector, are the most frequent mutational event in papillary thyroid tumors. These observations support roles for Ras in the initiation and progression of thyroid tumors. A large proportion of papillary thyroid tumors exhibit amplification and rearrangement of the PKCepsilon gene, leading to the expression of an N-terminal fragment of PKCepsilon structurally similar to the V1 domain, a peptide that selectively inhibits PKCepsilon translocation. Interestingly, most papillary thyroid tumors exhibit decreased expression of PKCepsilon. Moreover, expression of the RET/PTC oncogene induced the selective translocation, followed by downregulation of PKCepsilon. PKCalpha expression is increased in follicular thyroid tumors, tumors that also harbor Ras mutations. It is our hypothesis that individual PKC isozymes play essential roles in the initiation and maintenance of thyroid cell transformation by Ras. Our preliminary data demonstrate that PKCdelta selectively reproduces the acute effects of oncogenic Ras on aberrant cell cycle progression and apoptosis; that PKCepsilon is required for Ras-induced morphological changes; that PKCs mimic the inhibitory effects of Ras on thyroid differentiation; and that Ras-transformed thyroid cells exhibit alterations in PKC expression and activity. The proposed studies investigate the roles of individual PKC isozymes in the initiation and maintenance of Ras transformation in rat thyroid cells. This will be accomplished using highly specific molecular reagents including adenoviruses for PKC isozymes, selective PKC peptide activators and inhibitors and RNA interference. This analysis will provide novel insight into the molecular mechanisms through which Ras dysregulates thyroid cell proliferation, differentiation and survival, and may give rise to the development of new strategies to selectively impair tumor cell proliferation and/or reactivate differentiated gene expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rap1Gap and Tumor Progression
  • 批准号:
    8471068
  • 项目类别:
  • 资助金额:
    $30.27万
  • 财政年份:
    2009
  • 负责人:
    JUDY L MEINKOTH
  • 依托单位:
Rap1Gap and Tumor Progression
  • 批准号:
    8257588
  • 项目类别:
  • 资助金额:
    $32.2万
  • 财政年份:
    2009
  • 负责人:
    JUDY L MEINKOTH
  • 依托单位:
Rap1Gap and Tumor Progression
  • 批准号:
    7580565
  • 项目类别:
  • 资助金额:
    $32.99万
  • 财政年份:
    2009
  • 负责人:
    JUDY L MEINKOTH
  • 依托单位:
Rap1Gap and Tumor Progression
  • 批准号:
    7866633
  • 项目类别:
  • 资助金额:
    $33.18万
  • 财政年份:
    2009
  • 负责人:
    JUDY L MEINKOTH
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: